NMN/NR (Nicotinamide Mononucleotide/Riboside) Cost in California 2026

Nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are both precursors that cells convert into NAD+, a coenzyme involved in energy metabolism and cellular repair. They are not the same molecule, and as of late 2022 they are not regulated the same way in the United States. That regulatory split, not a difference in raw ingredient cost, is the main reason NMN and NR are priced so differently for California residents in 2026.

The direct answer: NR is sold over the counter in California as a dietary supplement, typically in the range of $40 to $60 for a 30-day supply from major retailers, with no prescription required. NMN, since the FDA determined it had been under investigation as a new drug before its supplement marketing began, is generally only available as a compounded preparation through a licensed prescriber and a 503A or 503B compounding pharmacy, and cash prices reported by California pharmacies commonly fall in a wide $50 to $120 monthly range depending on dose and formulation. Neither figure is a fixed or regulated price, and both should be confirmed directly with a specific pharmacy before you budget around them.

The question worth asking first

Most cost pages for supplements assume the only variable is price. For NMN, the more useful question is: which access pathway applies to you, over-the-counter NR, a prescribed compounded NMN product, or a telehealth-initiated compounding pathway, because each pathway carries a different price ceiling, a different insurance treatment, and a different level of quality oversight. Choosing NR versus NMN is often a bigger cost decision than choosing which pharmacy fills the prescription.

FDA status: the fact that drives the price gap (verify date before citing)

The FDA has publicly addressed dietary supplement categories at fda.gov/food/dietary-supplements, and industry reporting has described NMN losing eligibility to be marketed as a dietary supplement because a company had already filed an investigational new drug (IND) application covering NMN before it appeared as a supplement ingredient. This is the generally cited explanation for why NMN moved toward compounded, prescription-only availability while NR, which did not have a competing IND filed before its supplement marketing began, remained available over the counter.

This regulatory history is reported consistently across trade and consumer coverage, but a specific FDA guidance letter or warning letter number was not available in the source material for this article, so readers relying on the exact date or docket number should verify it directly on fda.gov before treating it as a citable fact. What is stable and confirmable: NMN compounded products in California require a prescription and must be dispensed through a pharmacy licensed by the California State Board of Pharmacy, which oversees compounding under USP nonsterile and sterile preparation standards (pharmacy.ca.gov).

What NMN and NR actually cost (treat as directional, not quoted pricing)

Pricing below reflects the general range described by industry and retail reporting rather than a verified first-party price survey. Prices change, vary by pharmacy, and are not something HealthRX.com can confirm as current without contacting individual sellers.

• NR (Tru Niagen and similar branded products), OTC, 30-day supply: commonly reported around $40 to $60
• Compounded NMN, 250 mg capsules, 30-count, 503A pharmacy: commonly reported around $50 to $75
• Compounded NMN, 500 mg capsules, 30-count: commonly reported around $75 to $110
• Compounded NMN, sublingual formulations: often priced somewhat higher than oral capsules, reportedly due to formulation and stability costs, though head-to-head bioavailability data comparing sublingual and oral NMN in humans is limited

Subscription or auto-refill programs at some compounding pharmacies and at NR manufacturers are commonly advertised at a discount versus one-time purchase, but the size of that discount and its availability change over time and by vendor. Confirm current pricing and subscription terms directly with the pharmacy or manufacturer before assuming a specific dollar figure.

Does Medi-Cal cover NMN or NR?

Medi-Cal can, in principle, cover a compounded prescription drug with prior authorization when a prescriber documents medical necessity. In practice, NAD+ precursor therapy does not currently appear in major U.S. clinical treatment guidelines for any specific condition, and prior authorization approval for compounded NMN should be treated as uncommon rather than routine. If a request is denied, California's fair hearing process allows an appeal, and a prescriber can request a peer-to-peer review with the plan's medical director. NR, sold without a prescription, is not a Medi-Cal pharmacy benefit unless it appears on the program's covered over-the-counter list, which it does not as of this writing.

Confirm current Medi-Cal formulary and prior-authorization status directly with the Medi-Cal Rx contractor before relying on this summary, since drug coverage lists change.

Private insurance and HSA/FSA treatment

Major California commercial plans generally do not list NMN or NR on formulary, since NMN has no FDA-approved indication and NR is a supplement rather than a drug. A minority of employer-sponsored plans with lifestyle or longevity benefit riders may cover compounded NAD+ precursor therapy, but this is not standard and should be confirmed with your specific plan document, not assumed from general reporting.

The IRS allows HSA and FSA reimbursement for prescribed medications, including compounded preparations, per IRS Publication 502 (irs.gov/publications/p502). A compounded NMN prescription with proper documentation may qualify; an OTC NR supplement generally does not qualify unless a licensed clinician provides a letter of medical necessity on file with your plan administrator. Confirm eligibility with your HSA/FSA administrator, since interpretation varies by plan.

Compounding and telehealth pathways in California

California permits 503A pharmacies to prepare patient-specific NMN formulations against a valid prescription, under Board of Pharmacy oversight (pharmacy.ca.gov). To obtain compounded NMN you generally need a prescription from a licensed prescriber (MD, DO, NP, or PA), a 503A or 503B pharmacy licensed in California, and documentation that the product is for an individual patient rather than bulk resale.

California's telehealth statute (Business and Professions Code Section 2290.5, available at leginfo.legislature.ca.gov) permits prescribing following an appropriate audio-video examination and documentation of clinical rationale. The prescriber must hold an active California license or practice under a valid interstate compact. Telehealth consultation fees and bundled prescription-plus-compounding packages vary by platform; specific dollar figures should be confirmed with the individual telehealth service rather than treated as fixed.

Ask any compounding pharmacy for a current certificate of analysis showing third-party testing for NMN content, heavy metals, and microbial contamination before paying for a compounded product.

What the clinical evidence actually shows, and what it does not

The evidence base for NMN and NR in humans is early and should not be overstated. Several small randomized trials have measured whether these compounds raise blood NAD+ levels and whether that translates into measurable metabolic benefit. In general, published human trials have been short in duration (weeks, not years), have enrolled small numbers of participants (roughly a few dozen in most studies), and have reported NAD+ level increases fairly consistently, while downstream clinical outcomes such as insulin sensitivity, blood pressure, or body composition have shown mixed or inconsistent results across studies. No completed human trial has established an FDA-approved indication for either compound, and reported adverse events across published trials have generally been mild (flushing, transient GI upset).

Earlier versions of this article included specific quantitative results tied to PubMed identifiers, but these citations could not be independently confirmed against original sources during this update. Rather than repeat unverified figures about NAD precursor effects on metabolism or vascular function, such numbers have been omitted. Readers interested in particular NMN or NR trial outcomes should consult the original research papers through PubMed or the relevant journal rather than depending on third-party accounts.

Safety and monitoring

NAD+ precursors have generally shown a favorable short-term safety profile in the human trials that have been published, with mild and self-limited side effects being the most commonly reported issue. There is no established, guideline-backed monitoring protocol. Clinicians who prescribe compounded NMN sometimes order baseline and follow-up whole-blood NAD+ testing or liver function testing, but this reflects site-level clinical judgment rather than a professional society guideline. The Endocrine Society has not issued formal guidance on NAD+ precursor therapy.

Preclinical research has raised a theoretical question about whether NAD+ elevation could support tumor growth in certain cancer models; this has not been demonstrated in human studies and should be discussed directly with an oncologist or primary care physician by anyone with a current or past cancer diagnosis, or anyone on anticoagulant or diabetes medication, before starting either compound. This article does not provide individualized dosing guidance; dosing should be set by a prescribing clinician based on the individual's history.

Evidence boundary: what is established, what is not

Established: NR is currently sold as an OTC dietary supplement in the US; NMN compounded products require a prescription and 503A/503B pharmacy dispensing in California; California permits telehealth prescribing of compounded medications under documented conditions; Medi-Cal has a prior-authorization pathway for compounded drugs in general.

Plausible but not established in humans: that NMN and NR produce clinically meaningful, durable improvements in metabolic or aging-related outcomes beyond raising measured NAD+ levels; that sublingual NMN is meaningfully more bioavailable than oral NMN in humans.

Not established: any FDA-approved indication for NMN or NR; any professional guideline recommending NAD+ precursor therapy for a specific condition; a stable, verifiable statewide average cash price for either compound in California, since pricing is set independently by individual pharmacies and retailers and changes over time.

Verification checklist: stable facts versus facts you must re-check before paying

This distinction helps identify claims with stable evidence from those requiring current validation before making a supplement decision.

Stable, federal or regulatory facts (unlikely to change month to month):

• NMN's supplement-vs-drug regulatory status traces to an IND filing predating its supplement marketing, confirm current status at fda.gov/food/dietary-supplements
• NR retains dietary supplement status and does not require a prescription
• California 503A/503B compounding requires Board of Pharmacy licensure and USP compliance, verify a specific pharmacy's license at pharmacy.ca.gov
• California telehealth prescribing authority derives from Business and Professions Code Section 2290.5 (leginfo.legislature.ca.gov)
• Neither NMN nor NR has an FDA-approved indication for any condition

Date-sensitive facts you must re-verify before relying on them (check within days of use, not from this article):

• Current cash price at the specific compounding pharmacy or retailer you plan to use
• Whether your specific Medi-Cal managed care plan currently approves compounded NMN prior authorization requests
• Whether your specific commercial plan or employer benefit currently covers compounded NAD+ precursor therapy
• Whether your HSA/FSA administrator currently accepts compounded NMN as an eligible expense, and what documentation it requires
• Whether a specific telehealth platform's prescriber holds an active California license
• Whether a specific compounding pharmacy can currently provide a certificate of analysis for the batch you would receive

If any item in the second list cannot be confirmed directly with the payer or pharmacy in question, treat the associated price or coverage claim as unverified rather than final.

Common reader questions

Is NMN legal to buy in California? Compounded NMN is legal with a valid prescription from a licensed prescriber, dispensed through a California-licensed 503A or 503B pharmacy. Retail, non-prescription sale of NMN as a supplement is the part that changed; confirm current retail availability status directly with FDA guidance before assuming any product sold as an OTC supplement is compliant.

Is NR the same as NMN for cost purposes? No. NR is generally the lower-cost, no-prescription option. NMN generally requires a prescription and compounding pharmacy fulfillment, which adds clinician and pharmacy costs on top of the ingredient cost.

Will my insurance cover this? Most California commercial plans do not cover either compound. A prescribed, compounded NMN product may be HSA/FSA eligible if properly documented; OTC NR generally is not, absent a medical necessity letter. Confirm with your specific plan.

Does Medi-Cal pay for NMN? It can, through prior authorization, but approval is not routine given the lack of guideline-backed indications. Appeal rights exist if a request is denied.

References

• U.S. Food and Drug Administration, Dietary Supplements: https://www.fda.gov/food/dietary-supplements
• California State Board of Pharmacy, compounding oversight: https://www.pharmacy.ca.gov
• California Business and Professions Code Section 2290.5 (telehealth): https://leginfo.legislature.ca.gov
• Internal Revenue Service, Publication 502 (Medical and Dental Expenses): https://www.irs.gov/publications/p502

This article summarizes publicly available regulatory and pricing information for educational purposes. It is pending qualified clinical and pharmacy review. It does not provide individualized medical, dosing, or coverage advice. Confirm current pricing, formulary status, and prior authorization rules directly with your pharmacy, prescriber, and health plan before making a treatment or purchasing decision. Seek urgent care for any acute symptoms rather than relying on this article.